Invasive fungal infections are another top concern, as outlined by the World Health Organization’s Fungal Priority Pathogens ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Oral cefixime is a third-generation cephalosporin that has a similar antibacterial spectrum to ceftriaxone. Cefixime is ...

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the upcoming presentations of pemivibart data from ...

A new study presented at IDWeek 2024 reveals that race and socioeconomic vulnerabilities significantly impact vaccine uptake ...

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® ...

ATI-1701 provides full protection against lethal tularemia in animal models after one yearCompany to provide update on tularemia vaccine ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CA from October 16-19, 2024. Data to be presented at IDWeek 2024 include: ...